Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07280221
Enrolling by invitation Observational

WEgovy Real World Assessment of Weight Loss in Korea

NCT07280221 · tracked via the Priya Life Science South Korea tracker
Sponsor
Novo Nordisk A/S
Phase
Observational
Started
2025-11-10
Last updated
2026-09-30

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

Semaglutide →

Semaglutide: Semaglutide injection will be self-administered once weekly subcutaneously.

Study summary

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study. 3. Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label. 4. Male or female, aged ≥ 19 years at the time of signing the informed consent. Exclusion Criteria: 1. Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study. 2. Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice). 3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.

Primary outcome measure(s)

  • Percentage change in body weight — From baseline (week 0) to 24 weeks
    Percent (%)

Trial sites (18)

FacilityCityRegionStatus
National Health Insurance Corporation Ilsan Hospital Goyang-si Gyeonggi-do
Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do
Ajou University Hospital Suwon Gyeonggi-do
The Catholic University of Korea. Uijeongbu St. Mary's Hospital Uijeongbu-si Gyeonggi-do
Pusan National University Yangsan Hospital Yangsan Gyeongsangnam-do
Inje University Haeundae Paik Hospital Busan South Korea
Dong-A University Hospital Busan South Korea
Keimyung University Dongsan Hospital Daegu South Korea
Daejeon Endo Internal Medicine Clinic Daejeon South Korea
Konyang University Hospital Daejeon South Korea
Chung-Ang University Gwangmyeong Hospital Gwangmyeong-si, Gyeonggi-do South Korea
CHA Bundang Medical Center Seongnam-si, Gyeonggi-do South Korea
Seoul Happiness Clinic of internal medicine Seongnam-si, Gyeonggi-do South Korea
Chung-Ang University Hospital Seoul South Korea
Ewha Womans University Seoul Hospital Seoul South Korea
Korea University Guro Hospital Seoul South Korea
Uijeongbu Eulji university Hospital Uijeongbu-si, Gyeonggi-do South Korea
Yongin Severance Hospital Yongin-si South Korea

On this site

📄 Ozempic (semaglutide) drug profile →

More Novo Nordisk A/S trials in South Korea

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy Recruiting
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea Enrolling by invitation
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 Active, not recruiting
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow Active, not recruiting
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors Active, not recruiting

Other trials for the same condition

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Active, not recruiting
Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study Enrolling by invitation
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07280221 on ClinicalTrials.gov ↗ ← All trials in South Korea